Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYK2 | P29597 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | JAK2 | O60674 | 1/20 | 0.47 |
| ▸ | JAK1 | P23458 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.46 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.43 |
| ▸ | LCK | P06239 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL561714 | 0.82 | ALDH1A1 (0.47) | KMT2AMEN1NLRP3 | |
| SCHEMBL23212117 | 0.78 | NPC1 (0.52) | KMT2AMEN1LMNASMN1; SMN2POLB | |
| SCHEMBL13875546 | 0.78 | KMT2A (0.36) | KMT2AMEN1LMNASMN1; SMN2TP53 | |
| SCHEMBL19748 | 0.76 | KMT2A (0.61) | KMT2ASMN1; SMN2TP53POLB | |
| SCHEMBL4188965 | 0.75 | MEN1 (0.45) | KMT2AMEN1LMNAJAK2JAK1 | |
| SCHEMBL28876498 | 0.75 | P2RX7 (0.42) | KMT2AMEN1LMNAMAPTSMN1; SMN2 | |
| SCHEMBL6004361 | 0.75 | ATM (0.49) | KMT2AMEN1MAPTPOLB | |
| SCHEMBL23246023 | 0.75 | NPC1 (0.53) | KMT2AMEN1LMNASMN1; SMN2 | |
| SCHEMBL23246073 | 0.74 | GRM4 (0.57) | KMT2AMEN1LMNAMAPTSMN1; SMN2 | |
| SCHEMBL18010190 | 0.74 | KMT2A (0.33) | KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060183780-A1 | Pyrazole compounds useful in the treatment of inflammation | BIOLIPOX AB (SE) | 2006-08-17 | — | — | US | disclosed |
| EP-1603897-A1 | PYRAZOLE COMPOUNDS USEFUL IN THE TREATMENT OF INFLAMMATION | Biolipox AB (SE) | 2005-12-14 | — | — | EP | disclosed |
| WO-2004080999-A1 | PYRAZOLE COMPOUNDS USEFUL IN THE TREATMENT OF INFLAMMATION | BIOLIPOX AB (SE) | 2004-09-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060183780-A1 | Pyrazole compounds useful in the treatment of inflammation | ALOX15, ALOX12, ALOX15B | TYK2 1249/4885KMT2A 4358/4885MEN1 4278/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.